Delivery Order SPE2DB22D1002-SPE2DB25FLFH3
Award Date 7/25/25
Potential Completion Date 8/15/25
Potential Value $1.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $1,386.04 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a $3,465.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order is to be fulfilled at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for HYPERRAB 300 Unit/ml Vial pharmaceutical products with a ceiling value of $2,079.06 and a firm fixed price structure. The contract is set for ultimate completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The U.S. Defense Logistics Agency (DLA) awarded a $9,304.75 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HYPERRAB 300 Unit/mL vial medication. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,744.80 firm fixed-price delivery order is for the medical product "HYPERRAB 300 UNIT/ML VIAL 5ML" and has an ultimate completion date of April 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,270.10, is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of December 10, 2024. It is not associated with any set-aside designation, indicating open competition. AmerisourceBergen...